

## With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01

In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies. In parallel, the company will intensify preparations for studies in humans, known as clinical studies, which are scheduled to begin in 2022. CombiGene has now recruited Pernilla Fagergren to the position as Clinical Project Manager, which means that Pernilla will be responsible for preparing and running the first clinical study.

Pernilla Fagergren has a broad experience from academia and industry. She holds a PhD at Karolinska Institutet in Stockholm and has conducted research at Mount Sinai School of Medicine in New York, USA. Pernilla comes most recently from Merck AB where she worked as a medical advisor and manager in neurology. Prior to that, she worked as a researcher with early pharmaceutical projects at Karo Bio AB. Her expertise covers key areas such as drug development, project management and neuropharmacology. Pernilla also has extensive experience in national and international collaboration with physicians and leading medical opinion leaders. Pernilla will report to CombiGene's Chief Research and Development Officer Karin Agerman.



*preparation work for the first study in human within our epilepsy project CG01."*

*"I am incredibly pleased that we have succeeded in recruiting Pernilla Fagergren to CombiGene", says Karin Agerman. "Pernilla has just the deep knowledge of drug development and clinical studies that we are looking for. Her experience from international work in both industry and academia will be crucial as we step up the*

---

### About CombiGene AB

*CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies.*

*CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, [info@fnca.se](mailto:info@fnca.se).*

### For further information:

CombiGene AB (publ)  
Jan Nilsson, CEO  
Tel: +46 (0)704 66 31 63  
[jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

Bert Junno, Chairman of the board  
Tel: +46(0) 70 777 22 09  
[bert.junno@combigene.com](mailto:bert.junno@combigene.com)

***Please read **INGENEIOUS**, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. **INGENEIOUS** and press releases are available at [www.combigene.com](http://www.combigene.com)***